either is great but wondering
The Fly On The Wall
Breaking News Feed
( KITE )
Buy Opportunity Before ASCO Conference May 2015 - Cowen Outperform Rating
ADXS: Positive Phase I/II Data Reported on ADXS-HPV
3/17/15We maintain our Outperform rating for ADXS and raise our target to $18.00 per share from previous $15.00 per share based on the recent clinical achievements.
Could This Clinical-Stage Biotech Stock Soar in April?
By Motley Fool, March 12, 2015, 08:59:01 AM EDT
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from this strong interest, the research firm said. In Deceber,Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
3/5/15 Options Express